Cargando…
Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study
BACKGROUND: Neoadjuvant chemoradiotherapy is the treatment of choice in advanced rectal cancer, even though there are many patients who will not benefit from it. There are still no effective methods for predicting which patients will respond or not. The present study aimed to define the genomic prof...
Autores principales: | Molinari, Chiara, Ballardini, Michela, Teodorani, Nazario, Giannini, Massimo, Zoli, Wainer, Emiliani, Ermanno, Lucci, Enrico, Passardi, Alessandro, Rosetti, Paola, Saragoni, Luca, Guidoboni, Massimo, Amadori, Dino, Calistri, Daniele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3236016/ https://www.ncbi.nlm.nih.gov/pubmed/22099067 http://dx.doi.org/10.1186/1748-717X-6-161 |
Ejemplares similares
-
miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer
por: Molinari, Chiara, et al.
Publicado: (2016) -
EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015) -
Discrepancies between VEGF −1154 G>A Polymorphism Analysis Performed in Peripheral Blood Samples and FFPE Tissue
por: Marisi, Giorgia, et al.
Publicado: (2014) -
Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
por: Ulivi, Paola, et al.
Publicado: (2012) -
Detection of KRAS mutant alleles in circulating cell-free tumor DNA in colorectal cancer patients resistant to cetuximab
por: Del Re, Marzia, et al.
Publicado: (2014)